Beaufort Securities Breakfast Today including Fusion IP Proactive Investors UK Yesterday, Fusion IP announced that one of its portfolio companies, Diurnal, was granted approval for a Paediatric Investigation Plan from the European Medicines Agency (EMA) for a new formulation of hydrocortisone- Infacort. Diurnal is developing a ... |
